Zai Lab

Nov 09, 2021

•

Sep 30, 2021

Zai Lab Q3 2021 Earnings Report

Zai Lab entered into a collaboration and license agreement with Blueprint Medicines for BLU-945 and BLU-701 in Greater China.

Key Takeaways

Zai Lab and Blueprint Medicines announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China.

Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China.

Collaboration accelerates and expands global development of Blueprint Medicines’ next- generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China.

Blueprint Medicines will receive $25 million upfront payment.

Blueprint Medicines is eligible to receive up to $590 million in potential future milestone payments, and royalties.